Form 4: Theravance Biopharma Director, Deepika Pakianathan, Reports Stock Option Grant and Share Disposal
SEC Form 4 Filing
Director Deepika Pakianathan reports the acquisition of stock options and disposal of ordinary shares in Theravance Biopharma.
Summary
- On May 19, 2025, Deepika Pakianathan, a director of Theravance Biopharma, acquired 24,258 share options with an exercise price of $9.39, expiring on May 18, 2035.
- These options vest in installments over time, with full vesting contingent upon continued service.
- Pakianathan also disposed of 10,649 ordinary shares at $0, and now beneficially owns 58,065 ordinary shares.
- The transactions were reported on a Form 4 filing with the SEC.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock options and share disposal by a director. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard compensation and trading activity.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction provides information to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 05/19/2025 | Date of earliest transaction: Acquisition of share options and disposal of ordinary shares. |
| 05/18/2035 | Expiration date of the acquired share options. |
| 05/21/2025 | Date of signature on the Form 4 filing. |
Keywords
Theravance Biopharma, TBPH, Deepika Pakianathan, Form 4, Stock Options, Share Disposal, Director, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.